Your browser doesn't support javascript.
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.
Hastie, Kathryn M; Li, Haoyang; Bedinger, Daniel; Schendel, Sharon L; Dennison, S Moses; Li, Kan; Rayaprolu, Vamseedhar; Yu, Xiaoying; Mann, Colin; Zandonatti, Michelle; Diaz Avalos, Ruben; Zyla, Dawid; Buck, Tierra; Hui, Sean; Shaffer, Kelly; Hariharan, Chitra; Yin, Jieyun; Olmedillas, Eduardo; Enriquez, Adrian; Parekh, Diptiben; Abraha, Milite; Feeney, Elizabeth; Horn, Gillian Q; Aldon, Yoann; Ali, Hanif; Aracic, Sanja; Cobb, Ronald R; Federman, Ross S; Fernandez, Joseph M; Glanville, Jacob; Green, Robin; Grigoryan, Gevorg; Lujan Hernandez, Ana G; Ho, David D; Huang, Kuan-Ying A; Ingraham, John; Jiang, Weidong; Kellam, Paul; Kim, Cheolmin; Kim, Minsoo; Kim, Hyeong Mi; Kong, Chao; Krebs, Shelly J; Lan, Fei; Lang, Guojun; Lee, Sooyoung; Leung, Cheuk Lun; Liu, Junli; Lu, Yanan; MacCamy, Anna.
  • Hastie KM; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Li H; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Bedinger D; Carterra, 825 N. 300 W. Ste C309, Salt Lake City, UT 84103, USA.
  • Schendel SL; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Dennison SM; Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Li K; Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Rayaprolu V; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Yu X; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Mann C; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Zandonatti M; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Diaz Avalos R; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Zyla D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Buck T; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Hui S; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Shaffer K; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Hariharan C; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Yin J; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Olmedillas E; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Enriquez A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Parekh D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Abraha M; Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Feeney E; Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Horn GQ; Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Aldon Y; Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, Netherlands.
  • Ali H; Quadrucept Bio, Ltd., Cambridge CB23 6DW, UK.
  • Aracic S; Myrio Therapeutics Pty, Ltd., 1 Dalmore Drive, Scoresby, VIC 3179, Australia.
  • Cobb RR; National Resilience, Inc., 13200 NW Nano Ct., Alachua, FL 32615, USA.
  • Federman RS; Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.
  • Fernandez JM; Activemotif, Inc., 1914 Palomar Oaks Way, Suite 150, Carlsbad, CA 92008, USA.
  • Glanville J; Centivax, Inc., 201 Gateway Blvd., Floor 1, South San Francisco, CA 94080, USA.
  • Green R; Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.
  • Grigoryan G; Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.
  • Lujan Hernandez AG; Twist Bioscience, 681 Gateway Blvd., South San Francisco, CA 94080, USA.
  • Ho DD; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, 701 West 168th St., HHSC 1102, New York, NY 10032, USA.
  • Huang KA; Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital and Research Center for Emerging Viral Infections, Chang Gung University, Taoyuan, Taiwan.
  • Ingraham J; Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.
  • Jiang W; Shanghai Henlius Biotech, Inc., 9/F, Innov Tower, Zone A, no. 1801 Hongmei Road, Xuhui District, Shanghai, China.
  • Kellam P; Kymab, Ltd., The Bennet Building, Babraham Research Campus, Cambridge CB22 3AT, UK.
  • Kim C; Department of Infectious Disease, Imperial College, London SW7 2AZ, UK.
  • Kim M; Celltrion, Inc., Department of Research and Development, 23 Academy-ro Yeonsu-gu Incheon, Republic of Korea.
  • Kim HM; Celltrion, Inc., Department of Research and Development, 23 Academy-ro Yeonsu-gu Incheon, Republic of Korea.
  • Kong C; Celltrion, Inc., Department of Research and Development, 23 Academy-ro Yeonsu-gu Incheon, Republic of Korea.
  • Krebs SJ; Sanyou Biopharmaceuticals Co., Ltd., no. 188 Xinjunhuan Road, Building 6B-C, 3rd Floor, Minhang District, Shanghai 201114, China.
  • Lan F; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Lang G; Activemotif, Inc., 1914 Palomar Oaks Way, Suite 150, Carlsbad, CA 92008, USA.
  • Lee S; Shanghai Key Laboratory of Medical Epigenetics, International Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
  • Leung CL; Sanyou Biopharmaceuticals Co., Ltd., no. 188 Xinjunhuan Road, Building 6B-C, 3rd Floor, Minhang District, Shanghai 201114, China.
  • Liu J; Celltrion, Inc., Department of Research and Development, 23 Academy-ro Yeonsu-gu Incheon, Republic of Korea.
  • Lu Y; Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.
  • MacCamy A; Shanghai Henlius Biotech, Inc., 9/F, Innov Tower, Zone A, no. 1801 Hongmei Road, Xuhui District, Shanghai, China.
Science ; 374(6566): 472-478, 2021 Oct 22.
Article in English | MEDLINE | ID: covidwho-1434867
ABSTRACT
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in SARS-CoV-2 that could impair antibody defenses propagated in human-to-human transmission and spillover or spillback events between humans and animals. To develop prevention and therapeutic strategies, we formed an international consortium to map the epitope landscape on the SARS-CoV-2 spike protein, defining and structurally illustrating seven receptor binding domain (RBD)­directed antibody communities with distinct footprints and competition profiles. Pseudovirion-based neutralization assays reveal spike mutations, individually and clustered together in variants, that affect antibody function among the communities. Key classes of RBD-targeted antibodies maintain neutralization activity against these emerging SARS-CoV-2 variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunodominant Epitopes / Epitope Mapping / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / Antibodies, Viral Topics: Vaccines / Variants Limits: Humans Language: English Journal: Science Year: 2021 Document Type: Article Affiliation country: Science.abh2315

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunodominant Epitopes / Epitope Mapping / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / Antibodies, Viral Topics: Vaccines / Variants Limits: Humans Language: English Journal: Science Year: 2021 Document Type: Article Affiliation country: Science.abh2315